Abstract 1863
Background
The waiting time for cancer diagnosis and treatment could influence patients’ survival. However, in Poland the waiting time is still long. In Poland, medical care is financed by the government and free for patients, but in a situation of long waiting times for diagnostic tests or in cases where it is impossible to obtain some other health services, patients use the private sector. The rationale for this study was to figure out if there are any difficulties in the oncological system and assessment of whether patients have to use the private sector.
Methods
The study was carried out on a group of 384 patients who were being treated for malignant neoplasm in five oncological centers in Poland. A questionnaire was prepared specifically for this study and each patient was interviewed individually. The questionnaire was validated on a group of 20 patients. The measure of compliance was calculated using Cohen’s Kappa coefficient. The study protocol was approved by the Local Ethics Committee. All of the participants had submitted a signed consent form.
Results
202 women and 180 men (2 no data) were analyzed, median age 65 years. 67% of patients declared problems with getting social service and significant differences in getting social service were observed between various regions of Poland (p < 0.001). One third of patients (32%) used private services during the diagnostic process. Patients with higher education showed significantly more frequent problems (p = 0.03). 91% of patients declared difficulties during treatment. Those who showed significantly more frequent problems were: women (p = 0.04), younger patients (p = 0.0015), professionally active (p = 0.025) with higher education (p < 0.001), living in cities (p = 0.016). More than half of patients with higher education (54%) paid for healthcare services in comparison with patients with lower education levels (average 25%) (p < 0.001).
Conclusions
Cancer patients have some difficulties in the oncological system in Poland. The younger people, those with higher education, the professionally active, and those living in cities seem to be more aware of their rights. The proper solution could be to introduce corrections in oncological organization to avoid the need of using private services.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract